Canadian government awards US$493,000 to Medicago

Published: 11-Dec-2012
Research & Development Finance Pharmaceutical

To support development of new potency assays and process analytical technologies


Medicago, a Canadian biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), has been awarded up to US$493,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

The investment will support the development of new potency assays and process analytical technologies for Medicago's pandemic and seasonal influenza VLP vaccine candidates.

‘The development of the best assays that can ensure rapid release and availability of our influenza vaccine candidates aligns well with our strategy to deliver highly effective vaccines in the quickest possible manner,’ said Andy Sheldon, president and CEO of Medicago.

‘This contribution continues to demonstrate our long-standing relationship with NRC IRAP. We would sincerely like to thank them for their continued support and encouragement of Medicago.’

Medicago will work with NRC teams in Montreal and Ottawa to establish assays for more rapid lot release and better in-process control.

  • Companies:
  • Medicago
See more

You may also like

Design & Build

Medicago contributes CA$500,000 to help establish Class 3 containment laboratory at Université Laval

Read more
Remaining two-thirds of the funds will be provided by the City of Quebec and the research centre's foundation

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Design & Build

Medicago contributes CA$500,000 to help establish Class 3 containment laboratory at Université Laval

Remaining two-thirds of the funds will be provided by the City of Quebec and the research centre's foundation
Research & Development

Medicago to develop Ebola monoclonal antibodies for the Canadian government

Plant-based antibodies to be developed in mini-factories to fight the Sudan strain of the Ebola virus
Manufacturing

Medicago to build C$245m vaccine production facility in Quebec City, Canada

Will create 200 new highly skilled jobs by 2019
Finance

Mitsubishi Tanabe Pharma to acquire Medicago for $357m

Medicago has been collaborating with MTPC since 2012 to develop and commercialise rotavirus VLP-based vaccines
Manufacturing

Medicago produces rotavirus VLP vaccine candidate

It comprises all four structural antigens of rotavirus using its plant-based manufacturing platform
Research & Development

Medicago and Mitsubishi to develop next generation technology for plant production

Companies to evaluate closed hydroponic Plant Factory System
Research & Development

Medicago and Philip Morris sign influenza vaccines agreement for China

Medicago to receive up to US$12m in royalties
Subscribe now